Cell therapy with no discrete molecular drug target

Cell therapy with no discrete molecular drug target refers to a class of medical treatments where the active therapeutic agent is a population of living cells rather than a specific chemical or biological molecule (FDA, 2023). Unlike conventional drugs that interact with specific receptors or enzymes, these therapies exert their effects through multifaceted biological processes, such as the replacement of damaged tissues, the secretion of paracrine factors, or the modulation of the host's immune environment (Nature Reviews Drug Discovery, 2017). This designation is frequently applied to hematopoietic stem cell transplants, mesenchymal stem cell therapies, and other regenerative medicine products where the clinical outcome is the result of the cells' integrated biological functions (NIH, 2022). Because the "target" is often a physiological state or a systemic deficiency rather than a single molecule, these therapies require unique approaches for standardization and safety monitoring. Common applications include treating hematologic malignancies, autoimmune disorders, and degenerative conditions where traditional molecular targeting is insufficient (PubMed, 2021).

Other names

Cellular therapyCell-based therapyNon-molecular target therapyCytotherapy

The mechanism of action involves the administration of live cells that provide therapeutic effects through cell replacement, paracrine signaling, and complex modulation of the host immune system (Nature Reviews Drug Discovery, 2017).